A woman's heart

Michael S. Ewer, Stefan Glück

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer. although major clinical trials of the aromatase inhibitors (Als) anastrozole. letrozole. and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The Als inhibit the conversion of androgens to estrogen in postmenopausal women; consequently. their mechanism of action differs from that of tamoxifen. Accordingly. although it has been observed that tamoxifen has some favorable effects on cardiovascular risk. such as reducing total cholesterol levels. because of its partial estrogen-agonist properties. no such effects exist for the Als. Some studies. particularly those that compare the Als with tamoxifen. have suggested a less favorable impact of adjuvant Al therapy on cardiovascular risk. Comorbid conditions. including cardiovascular disease. emerge as competing causes of death as women with breast cancer continue to live longer. and the potential impact of adjuvant therapies on cardiovascular risk becomes an increasingly important consideration for clinicians.

Original languageEnglish
Pages (from-to)1813-1826
Number of pages14
JournalCancer
Volume115
Issue number9
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Tamoxifen
exemestane
letrozole
Breast Neoplasms
Estrogens
Cardiovascular Diseases
Aromatase Inhibitors
Therapeutics
Androgens
Cause of Death
Cholesterol
Clinical Trials

Keywords

  • Anastrozole
  • Aromatase inhibitors
  • Breast cancer
  • Cardiovascular disease
  • Exemestane
  • Letrozole
  • Tamoxifen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ewer, M. S., & Glück, S. (2009). A woman's heart. Cancer, 115(9), 1813-1826. https://doi.org/10.1002/cncr.24219

A woman's heart. / Ewer, Michael S.; Glück, Stefan.

In: Cancer, Vol. 115, No. 9, 01.05.2009, p. 1813-1826.

Research output: Contribution to journalArticle

Ewer, MS & Glück, S 2009, 'A woman's heart', Cancer, vol. 115, no. 9, pp. 1813-1826. https://doi.org/10.1002/cncr.24219
Ewer MS, Glück S. A woman's heart. Cancer. 2009 May 1;115(9):1813-1826. https://doi.org/10.1002/cncr.24219
Ewer, Michael S. ; Glück, Stefan. / A woman's heart. In: Cancer. 2009 ; Vol. 115, No. 9. pp. 1813-1826.
@article{3cbbfe932fc44673be01b154146f368d,
title = "A woman's heart",
abstract = "Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer. although major clinical trials of the aromatase inhibitors (Als) anastrozole. letrozole. and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The Als inhibit the conversion of androgens to estrogen in postmenopausal women; consequently. their mechanism of action differs from that of tamoxifen. Accordingly. although it has been observed that tamoxifen has some favorable effects on cardiovascular risk. such as reducing total cholesterol levels. because of its partial estrogen-agonist properties. no such effects exist for the Als. Some studies. particularly those that compare the Als with tamoxifen. have suggested a less favorable impact of adjuvant Al therapy on cardiovascular risk. Comorbid conditions. including cardiovascular disease. emerge as competing causes of death as women with breast cancer continue to live longer. and the potential impact of adjuvant therapies on cardiovascular risk becomes an increasingly important consideration for clinicians.",
keywords = "Anastrozole, Aromatase inhibitors, Breast cancer, Cardiovascular disease, Exemestane, Letrozole, Tamoxifen",
author = "Ewer, {Michael S.} and Stefan Gl{\"u}ck",
year = "2009",
month = "5",
day = "1",
doi = "10.1002/cncr.24219",
language = "English",
volume = "115",
pages = "1813--1826",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "9",

}

TY - JOUR

T1 - A woman's heart

AU - Ewer, Michael S.

AU - Glück, Stefan

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer. although major clinical trials of the aromatase inhibitors (Als) anastrozole. letrozole. and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The Als inhibit the conversion of androgens to estrogen in postmenopausal women; consequently. their mechanism of action differs from that of tamoxifen. Accordingly. although it has been observed that tamoxifen has some favorable effects on cardiovascular risk. such as reducing total cholesterol levels. because of its partial estrogen-agonist properties. no such effects exist for the Als. Some studies. particularly those that compare the Als with tamoxifen. have suggested a less favorable impact of adjuvant Al therapy on cardiovascular risk. Comorbid conditions. including cardiovascular disease. emerge as competing causes of death as women with breast cancer continue to live longer. and the potential impact of adjuvant therapies on cardiovascular risk becomes an increasingly important consideration for clinicians.

AB - Adjuvant therapy in postmenopausal women with breast cancer may contribute to the expression of underlying cardiovascular disease or expose the heart to additional toxicities. Tamoxifen remains an important component of endocrine therapy for breast cancer. although major clinical trials of the aromatase inhibitors (Als) anastrozole. letrozole. and exemestane suggest that these agents are more effective and better tolerated alternatives to tamoxifen. The Als inhibit the conversion of androgens to estrogen in postmenopausal women; consequently. their mechanism of action differs from that of tamoxifen. Accordingly. although it has been observed that tamoxifen has some favorable effects on cardiovascular risk. such as reducing total cholesterol levels. because of its partial estrogen-agonist properties. no such effects exist for the Als. Some studies. particularly those that compare the Als with tamoxifen. have suggested a less favorable impact of adjuvant Al therapy on cardiovascular risk. Comorbid conditions. including cardiovascular disease. emerge as competing causes of death as women with breast cancer continue to live longer. and the potential impact of adjuvant therapies on cardiovascular risk becomes an increasingly important consideration for clinicians.

KW - Anastrozole

KW - Aromatase inhibitors

KW - Breast cancer

KW - Cardiovascular disease

KW - Exemestane

KW - Letrozole

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=65649119341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65649119341&partnerID=8YFLogxK

U2 - 10.1002/cncr.24219

DO - 10.1002/cncr.24219

M3 - Article

C2 - 19235248

AN - SCOPUS:65649119341

VL - 115

SP - 1813

EP - 1826

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 9

ER -